Loading clinical trials...

A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia | Clinical Trials | Clareo Health

TERMINATED

A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia

A Study to Confirm the Presence of Recurrent or Persistent Cushing's Syndrome in Patients With Clinical Signs or Symptoms of Hypercortisolemia Who Have Been Treated for Cushing's Disease

NCT00796783•Corcept Therapeutics

View on ClinicalTrials.gov

Summary

This is an observational study to confirm the presence of recurrent or persistent endogenous Cushing's syndrome in patients who have had primary surgical and/or radiation therapy for Cushing's disease and continue to manifest symptoms and signs of hypercortisolemia.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Are at least 18 years of age.
•Have a presumptive diagnosis of Cushing's disease (Cushing's syndrome due to an ACTH secreting pituitary tumor).
•Have previously had pituitary surgery and/or pituitary radiation with the intent of curing or treating Cushing's disease.
•Have clinical symptoms and signs of hypercortisolism.
•Are able to provide written informed consent.
•Are expected to complete the study.

Exclusion Criteria

•Are surgical candidates for pituitary surgery or have had pituitary surgery within 8 weeks before screening.
•Have taken any medication that may interfere with protocol testing procedures within 30 days of initial screening (phenobarbital, phenytoin, carbamazepine, oxcarabazepine, primidone, rifampin, rifapentine, rifabutin, ethosuximide, pioglitazone, efavirenz, neviparine, modafinil, St. Johns wort, glucorticoids, estrogen containing oral contraceptives).
•Have received investigational treatment (drug, biologic agent or device) within 30 days of screening.
•Have a non-endogenous source of hypercortisolemia such as factitious hypercortisolemia (exogenous source of glucocorticoid, iatrogenic Cushing's syndrome), factitious or therapeutic use of ACTH.
•Have Pseudo-Cushing's syndrome. Subjects with suspected Pseudo-Cushing's syndrome such as those with severe obesity, major depression or a history of alcoholism.
•Uncontrolled, clinically significant hypothyroidism or hyperthyroidism.
•Have renal failure as defined by a serum creatinine of 202 mg/dL.
•Elevated total bilirubin (\>1.5x ULN), elevated ALT(\>3x ULN) or AST (\>3x ULN).

Locations (3)

AMCR Institute Inc.

Escondido, California, United States

The Center for Diabetes and Endocrine Care

Hollywood, Florida, United States

Diabetes and Glandular Disease Research

San Antonio, Texas, United States

Key Dates

Start Date

February 1, 2009

Primary Completion Date

June 1, 2010

Last Updated

June 20, 2014

Enrollment

ACTUAL participants

Conditions

Cushing's Syndrome

Interventions

Cushing's syndrome confirmation

DRUG

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

NCT05382156

Endogenous Cushing's Syndrome

View study

COMPLETED

Cardiovascular Status in Patients With Endogenous Cortisol Excess (Cushing's Syndrome)

NCT03880513

Endogenous Cushing's Syndrome

View study

COMPLETEDPHASE2

Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

NCT02468193

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 20, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia

Inclusion Criteria

Exclusion Criteria

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

Cardiovascular Status in Patients With Endogenous Cortisol Excess (Cushing's Syndrome)

Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery

Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome

A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease